Figure 3.

Clinical scores of mice during 54 days after EAE induction (A); ratio of clinical score increase on day 54 in relation to day 14 in the control and test groups (B); ratio of clinical score increase on day 24 in relation to day 14 in the control and high-dose groups (C).

Notes: The clinical score from each group at the end of the experiment (day 54) was divided over the clinical score from each group at the beginning of the treatment (day 14) to demonstrate the efficacy of the nanocomplex in controlling EAE progression by using mathematical logic (B); the clinical score on day 24 (when the clinical score was the highest in the control group) was divided over the clinical score on day 14 (the beginning of the treatment) to mathematically indicate the success of high-dose MSc1 in deferring disease progression (C).

Abbreviation: EAE, experimental autoimmune encephalomyelitis.